BIOSTEM TECHNOLOGIES
BSEM evidence brief
What we can confirm
- Market Cap:
- $76.9M
What it means
What to watch
Prepared research question
What matters most for BSEM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BSEM
BioStem Technologies (BSEM) is a regenerative medicine company that develops, manufactures, and commercializes perinatal tissue allograft products, with a focus on wound care and surgical applications.
Key risk: Operating losses
Market Cap
$76.9M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 3 clinical trials for BIOSTEM TECHNOLOGIES.
BioStem Technologies (BSEM) is a regenerative medicine company that develops, manufactures, and commercializes perinatal tissue allograft products, with a focus on wound care and surgical applications.
- Cash & equivalents of $7.0M as of 2026-06-30 [sec].
- Total revenue of $7.9M for the quarter ended June 30, 2026, representing 29% sequential growth [sec][news·2026-08-12].
- Net income of -$9.0M as of 2026-06-30 [sec].
- Shareholders' equity of $27.6M and total debt of $1.0M as of 2026-06-30 [sec].
- Uplisted to the Nasdaq Capital Market on August 7, 2026 [news·2026-08-06].
What works
- Revenue grew 29% sequentially to $7.9M in Q2 2026, and the company raised its full-year 2026 revenue guidance [news·2026-08-12].
- VENDAJE® and VENDAJE AC® were added to existing contracts with Vizient and Premier, expanding hospital access for the BioRetain® wound care line [news·2026-09-04].
- The company secured a $40 million Committed Equity Facility with Roth Principal Investments, providing potential capital for growth [news·2026-09-18].
- BioStem strengthened its patent portfolio with a newly issued U.S. patent and pending allowances in the U.S. and Mexico for placental allograft and umbilical tissue technologies [news·2026-10-01].
What to weigh
- Net income was -$9.0M as of 2026-06-30, indicating ongoing operating losses [sec].
- Cash & equivalents of $7.0M as of 2026-06-30 may be limited relative to the scale of operations and losses [sec].
- The company relies on equity-based financing (CEF and private placement) which can dilute existing shareholders [news·2026-09-18][news·2026-09-30].
- The company recently uplisted from OTC to Nasdaq, which may increase regulatory and reporting burdens [news·2026-08-06].
From the filings
Quoted directly from source documents.
Revenue growth and guidance raise
“Generates 29% sequential revenue growth, increasing to $7.9 million;Raises full-year 2026 revenue guidance”
News · August 12, 2026
Hospital channel expansion
“VENDAJE® and VENDAJE AC® have been added to the Company's existing contracts with Vizient, Inc. and Premier, Inc.”
News · September 4, 2026
Committed Equity Facility secured
“it has entered into a $40 million Committed Equity Facility (the “CEF”) with Roth Principal Investments, LLC”
News · September 18, 2026
Patent portfolio strengthening
“Newly issued U.S. Patent and pending allowances in the U.S. and Mexico extend protection for the company's sterile placental allograft, micronized wound care, and umbilical cord extract technologies”
News · October 1, 2026
Risks & what to watch (4)›
Key risks
- Operating losses — Net income of -$9.0M as of 2026-06-30 indicates ongoing unprofitability [sec].
- Limited cash runway — Cash & equivalents of $7.0M as of 2026-06-30 may be insufficient to sustain operations without additional financing [sec].
- Shareholder dilution — Reliance on equity-based financing (CEF and private placement) may dilute existing shareholders [news·2026-09-18][news·2026-09-30].
- Nasdaq compliance burden — Recent uplisting to Nasdaq increases regulatory and reporting requirements [news·2026-08-06].
What to watch
- Future revenue growth trajectory and ability to achieve profitability, given the 29% sequential growth in Q2 2026 [news·2026-08-12].
- Utilization of the $40 million Committed Equity Facility and its impact on cash position and dilution [news·2026-09-18].
- Expansion of hospital contracts through Vizient and Premier, and its effect on product adoption [news·2026-09-04].
- Progress on patent allowances in the U.S. and Mexico, which could strengthen competitive positioning [news·2026-10-01].
Sources: News · Generated October 5, 2026 · How we verify sources →
Run BIOSTEM TECHNOLOGIES through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BIOSTEM TECHNOLOGIES facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Frequently asked questions
What is the AI investment thesis for BIOSTEM TECHNOLOGIES?
BioStem Technologies (BSEM) is a regenerative medicine company that develops, manufactures, and commercializes perinatal tissue allograft products, with a focus on wound care and surgical applications.
Who is the CEO of BIOSTEM TECHNOLOGIES?
Mr. Jason V. Matuszewski is the chief executive officer of BIOSTEM TECHNOLOGIES (BSEM).
Where is BIOSTEM TECHNOLOGIES headquartered?
BIOSTEM TECHNOLOGIES (BSEM) is headquartered in Fort Lauderdale, FL, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.